Search

Your search keyword '"Vabret, Astrid"' showing total 298 results
Start Over Author "Vabret, Astrid" Language english
298 results on '"Vabret, Astrid"'

1. Human metapneumovirus infection is associated with a substantial morbidity and mortality burden in adult inpatients

Author

Philippot, Quentin, Rammaert, Blandine, Dauriat, Gaëlle, Daubin, Cédric, Schlemmer, Frédéric, Costantini, Adrien, Tandjaoui-Lambiotte, Yacine, Neuville, Mathilde, Desrochettes, Emmanuelle, Ferré, Alexis, Contentin, Laetitia Bodet, Lescure, François-Xavier, Megarbane, Bruno, Belle, Antoine, Dellamonica, Jean, Jaffuel, Sylvain, Meynard, Jean-Luc, Messika, Jonathan, Lau, Nicolas, Terzi, Nicolas, Runge, Isabelle, Sanchez, Olivier, Zuber, Benjamin, Guerot, Emmanuel, Rouze, Anahita, Pavese, Patricia, Bénézit, François, Quenot, Jean-Pierre, Souloy, Xavier, Fanton, Anne Lyse, Boutoille, David, Bunel, Vincent, Vabret, Astrid, Gaillat, Jacques, Bergeron, Anne, Lapidus, Nathanaël, Fartoukh, Muriel, and Voiriot, Guillaume

Published
2024
Full Text
View/download PDF

2. Unique Changes in the Incidence of Acute Chest Syndrome in Children With Sickle Cell Disease Unravel the Role of Respiratory Pathogens: A Time Series Analysis

Author

Assad, Zein, Valtuille, Zaba, Rybak, Alexis, Kaguelidou, Florentia, Lazzati, Andrea, Varon, Emmanuelle, Pham, Luu-Ly, Lenglart, Léa, Faye, Albert, Caseris, Marion, Cohen, Robert, Levy, Corinne, Vabret, Astrid, Gravey, François, Angoulvant, François, Koehl, Bérengère, and Ouldali, Naïm

Published
2024
Full Text
View/download PDF

5. Effect of Tenofovir Disoproxil Fumarate and Emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: A pilot, randomized, open-label phase 2 trial

Author

Parienti, Jean-Jacques, Prazuck, Thierry, Peyro-Saint-Paul, Laure, Fournier, Anna, Valentin, Cécile, Brucato, Sylvie, Verdon, Renaud, Sève, Aymeric, Colin, Mathilda, Lesne, Fabien, Guinard, Jérome, Ar Gouilh, Meriadeg, Dina, Julia, Vabret, Astrid, and Hocqueloux, Laurent

Published
2021
Full Text
View/download PDF

6. Healthcare associated coronavirus disease 2019 among health care workers in Normandy, France: a multi-center study

Author

Allaire, Alexandra, Auclair, Valérie, Krug, Sophie Beuve, Borderan, Guy-Claude, Chauvin, Corine, Dargere, Sylvie, Degallaix, Dominique, Delhomme, Joël, Erouart, Stéphane, Hautemaniere, Alexis, Ionescu, Paul, Le Foulon, François-Xavier, Lefflot, Stéphanie, Lefol-Seillier, Elisabeth, Levallois, Marie-Line, Martel, Mélanie, Michon, Jocelyn, Olliver, Dominique, Thomas-hervieu, Aurélie, Vabret, Astrid, Vaucelle, Carole, Verdon, Renaud, Thibon, Pascal, Breton, Pierre, Mouet, Audrey, Bidon, Antoine, Haupais, François, Darrigan, Caroline, Gautier, Pauline, Letourneur, Thomas, Perillieux, Emeline, Seguineau, Charles, Thibon, Paul, Henry, Liliane, Ar Gouilh, Meriadeg, Borgey, France, and Le Hello, Simon

Published
2021
Full Text
View/download PDF

8. Fatal Measles Inclusion-Body Encephalitis in Adult with Untreated AIDS, France

Author

Rodriguez, Christophe, Gouilh, Meriadeg Ar, Weiss, Nicolas, Stroer, Sebastian, Mokhtari, Karima, Seilhean, Danielle, Mathon, Bertrand, Demontant, Vanessa, N'Debi, Melissa, Gricourt, Guillaume, Woerther, Paul-Louis, Pawlotsky, Jean-Michel, Stefic, Karl, Marlet, Julien, Dequin, Pierre-Francois, Guillon, Antoine, Pourcher, Valerie, Boutolleau, David, Vabret, Astrid, and Burrel, Sonia

Subjects
Measles -- Care and treatment -- Development and progression, Highly active antiretroviral therapy, AIDS (Disease) -- Development and progression -- Care and treatment, Seizures (Medicine) -- Care and treatment -- Development and progression, Encephalitis -- Care and treatment -- Development and progression, Health
Abstract

We report a fatal case of measles inclusion-body encephalitis in a 28-year-old woman from Romania living in France who had untreated AIDS. She was initially admitted to the hospital on [...]

Published
2020
Full Text
View/download PDF

9. Unravelling the acute respiratory infection landscape: virus type, viral load, health status and coinfection do matter.

Author

Petat, Hortense, Corbet, Sandrine, Leterrier, Bryce, Vabret, Astrid, and Gouilh, Meriadeg Ar

Subjects
VIRAL load, RESPIRATORY infections, MIXED infections, PARAINFLUENZA viruses, VIRUS diseases, RESPIRATORY syncytial virus, INFANT care
Abstract

Introduction: Acute respiratory infections (ARI) are the most common infections in the general population and are mainly caused by respiratory viruses. Detecting several viruses in a respiratory sample is common. To better understand these viral codetections and potential interferences, we tested for the presence of viruses and developed quantitative PCR (Polymerase Chain Reaction) for the viruses most prevalent in coinfections: human rhinovirus (HRV) and respiratory syncytial virus (RSV), and quantified their viral loads according to coinfections and health status, age, cellular abundance and other variables. Materials and methods: Samples from two different cohorts were analyzed: one included hospitalized infants under 12 months of age with acute bronchiolitis (n=719) and the other primary care patients of all ages with symptoms of ARI (n=685). We performed Multiplex PCR on nasopharyngeal swabs, and quantitative PCR on samples positive for HRV or/and RSV to determine viral loads (VL). Cellular abundance (CA) was also estimated by qPCR targeting the GAPDH gene. Genotyping was performed either directly from first-line molecular panel or by PCR and sequencing for HRV. Results: The risks of viral codetection were 4.1 (IC95[1.8; 10.0]) and 93.9 1 (IC95 [48.7; 190.7]) higher in infants hospitalized for bronchiolitis than in infants in primary care for RSV and HRV respectively (p<0.001). CA was higher in samples positive for multiple viruses than in mono-infected or negative samples (p<0.001), and higher in samples positive for RSV (p<0.001) and HRV (p<0.001) than in negative samples. We found a positive correlation between CA and VL for both RSV and HRV. HRV VL was higher in children than in the elderly (p<0.05), but not RSV VL. HRV VL was higher when detected alone than in samples coinfected with RSV-A and with RSV-B. There was a significant increase of RSV-A VL when codetecting with HRV (p=0.001) and when co-detecting with RSV-B+HRV versus RSV-A+ RSV-B (p=0.02). Conclusions: Many parameters influence the natural history of respiratory viral infections, and quantifying respiratory viral loads can help disentangle their contributions to viral outcome. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Yellow fever vaccine-associated neurologic and viscerotropic disease: a 10-year case series of the French National Reference Center for Arboviruses with clinical and immunological insights.

Author

Hir, Anne Le, Durand, Guillaume A, Boucraut, José, Garnier, Annabelle, Mura, Marie, Diamantis, Sylvain, Carles, Michel, Durand, Claire, Schweitzer, Cyril, Audouard, Claire, Decroix, Véronique, Boyez, Romain, Dendriessche, Anne Van, Leclancher, Alexandre, Kaphan, Elsa, Closel, Luce Barbat du, Verdon, Renaud, Cheyron, Damien du, Vabret, Astrid, and Vergnon, Delphine

Subjects
YELLOW fever, NEUROLOGICAL disorders, VACCINE effectiveness, ARBOVIRUSES, CEREBROSPINAL fluid, AUTOIMMUNE diseases
Abstract

Background Immunization against the Yellow fever virus (YFV) with the 17D live-attenuated vaccine is the most effective way to prevent the disease. However, unexpected severe adverse events can occur. They consist in a neurological impairment - neurological disease (YEL-AND), a YF-like illness - viscerotropic disease (YEL-AVD) or anaphylaxis. In this article, we describe the epidemiology, clinical and biological features of YEL-AND and YEL-AVD cases reported to the French National Reference Center for Arboviruses (NRCA) in the past 10 years. Methods We conducted a national, retrospective study using the database of the NRCA from June 2012 to June 2022. All patients whose biological samples were sent to the NRCA for detection of YFV by serology and/or RT-qPCR for a suspected vaccine-associated adverse event were included. We collected data by reading medical records and conducted complementary neuro-immunological analysis, followed by a search for autoimmunity against type-1-interferon when samples were available at the NRCA. Results There were 10 cases of YEL-AND and 2 cases of YEL-AVD reported to the NRCA in the past 10 years, which represented an overall incidence of 0.6 for 100 000 doses. A total of 6/12 cases were previously healthy patients (50%, mean age 31 years), and 4/12 cases had cardiovascular co-morbidities (42%, mean age 56 years). The majority of YEL-AND had a favourable outcome at 6 months of follow up. One YEL-AVD patient passed. In secondary analyses, we evidenced a significant blood cerebrospinal fluid (CSF) barrier dysfunction, without intrathecal synthesis of immunoglobulin and without argument for a neuron damage. We further detected a significant rate of anti-type-1alpha interferon antibodies in 3/10 tested patients (2 YEL-AND and 1 YEL-AVD). Conclusion YEL-AND and YEL-AVD are rare events that can underlie defect in the innate immunity of apparently healthy or mild co-morbid subjects. Outcome was generally favourable in the YEL-AND cases of our series, but still life-threatening or even fatal in the YEL-AVD cases. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. High-risk exposure without personal protective equipment and infection with SARS-CoV-2 in-hospital workers - The CoV-CONTACT cohort

Author

Tubiana, Sarah, Burdet, Charles, Houhou, Nadhira, Thy, Michael, Manchon, Pauline, Blanquart, François, Charpentier, Charlotte, Guedj, Jérémie, Alavoine, Loubna, Behillil, Sylvie, Leclercq, Anne, Lucet, Jean-Christophe, Yazdanpanah, Yazdan, Attia, Mikaël, Demeret, Caroline, Rose, Thierry, Bielicki, Julia Anna, Bruijning-Verhagen, Patricia, Goossens, Herman, Descamps, Diane, van der Werf, Sylvie, Lina, Bruno, Duval, Xavier, Abad, Fanny, Abry, Dominique, Allain, Jean-Sébastien, Amiel-Taieb, Karline, Audoin, Pierre, Augustin, Shana, Ayala, Sandrine, Bansard, Hélène, Bertholon, Fréderique, Boissel, Nolwenn, Botelho-Nevers, Elisabeth, Bouiller, Kévin, Bourgeon, Marilou, Boutrou, Mathilde, Brick, Lysiane, Bruneau, Léa, Caumes, Eric, Chabouis, Agnès, Chan Thien, Eric, Chirouze, Catherine, Coignard, Bruno, Costa, Yolande, Costenoble, Virginie, Cour, Sylvie, Cracowski, Claire, Cracowski Jean, Luc, Deplanque, Dominique, Dequand, Stéphane, Desille-Dugast, Mireille, Desmarets, Maxime, Detoc, Maelle, Dewitte, Marie, Djossou, Felix, Ecobichon, Jean-Luc, Elrezzi, Elise, Faurous, William, Fortuna, Viviane, Fouchard, Julie, Gantier, Emilie, Gautier, Céline, Gerardin, Patrick, Gerset, Sandrine, Gilbert, Marie, Gissot, Valérie, Guillemin, Francis, Hartard, Cédric, Hazevis, Béatrice, Hocquet, Didier, Hodaj, Enkelejda, Ilic-Habensus, Emila, A, Jeudy, Jeulin, Helene, Kane, Maty, Kasprzyk, Emmanuelle, Kikoine, John, Laine, Fabrice, Laviolle, Bruno, Lebeaux, David, Ledru, Eric, Lefevre, Benjamin, Legoas, Carole, Legrand, Amélie, Legrand, Karine, Lehacaut, Jonathan, Lehur, Claire, Lemouche, Dalila, Lepiller, Quentin, Lepuil, Sévérine, Letienne, Estelle, Lucarelli, Aude, Madeline, Isabelle, Maillot, Adrien, Malapate, Catherine, Malvy, Denis, Mandic, Milica, Marty-Quinternet, Solène, Meghadecha, Mohamed, Mergeay-Fabre, Mayka, Mespoulhe, Pauline, Meunier, Alexandre, Migaud, Maria-Claire, Motiejunaite, Justina, Nathalie, Gay, Nguyen, Duc, Oubbea, Soumaya, Pagadoy, Maïder, Paris, Adeline, Paris, Christophe, Payet, Christine, Peiffer-Smadja, Nathan, Perez, Lucas, Perreau, Pauline, Pierrez, Nathalie, Pistone, Thierry, Postolache, Andreea, Rasoamanana, Patrick, Reminiac, Cécile, Rexah, Jade, Roche-Gouanvic, Elise, Rousseau, Alexandra, Schoemaecker, Betty, Simon, Sandrine, Soler, Catherine, Somers, Stéphanie, Sow, Khaly, Tardy, Bernard, Terzian, Zaven, Tournier, Anne, Tyrode, Sandrine, Vauchy, Charline, Verdon, Renaud, Vernet, Pauline, Vignali, Valérie, Waucquier, Nawal, Do Thi Thu, Huong, Laouénan, Cédric, Mentre, France, Pauline, Manchon, Dechanet, Aline, Letrou, Sophie, Quintin, Caroline, Frezouls, Wahiba, Le Hingrat, Quentin, Damond, Florence, Descamps, Dianes, Visseaux, Benoit, Vabret, Astrid, Bouscambert, Maud, Gaillanne, Laurence, Benmalek, Nabil, Attia, Mikael, Barbet, Marion, Petres, Stéphane, Escriou, Nicolas, Goyard, Sophie, Kafif, Ouifiya, Piquard, Valentine, Mailles, Alexandra, Simondon, Anne, Dreyere, Marion, Morel, Bruno, Vesval, Thiphaine, Amat, Karine, Ammour, Douae, Aqourras, Khadija, Couffin-Cadiergues, Sandrine, Delmas, Christelle, Desan, Vristi, Jean, Michel Doute, Esperou, Hélène, Hendou, Samia, Kouakam, Christelle, Le Meut, Guillaume, Lemestre, Soizic, Leturque, Nicolas, Marcoul, Emmanuelle, Nguefang, Solange, Roufai, Layidé, Abel, Laurent, Caillat-Zucman, Sophie, Study Group, Covcontact, Centre d'investigation Clinique [CHU Bichat] - Épidémiologie clinique (CIC 1425), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre interdisciplinaire de recherche en biologie (CIRB), Labex MemoLife, École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Collège de France (CdF (institution))-Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI Paris), Université Paris sciences et lettres (PSL)-École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Génétique Moléculaire des Virus à ARN - Molecular Genetics of RNA Viruses (GMV-ARN (UMR_3569 / U-Pasteur_2)), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae [Paris] (CNR - laboratoire coordonnateur), Institut Pasteur [Paris] (IP), Hôpital Beaujon [AP-HP], Physique des fonctions biologiques / Physics of Biological Functions, Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), Biologie Cellulaire des Lymphocytes - Lymphocyte Cell Biology, Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), St George's, University of London, University Children’s Hospital Basel = Hôpital pédiatrique universitaire des deux Bâle [Bâle, Suisse] (UKBB), University Medical Center [Utrecht], Universiteit Antwerpen = University of Antwerpen [Antwerpen], Virology and human respiratory Pathologies - Virology and human respiratory Pathologies (VirPath), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre National de Référence des Virus des Infections Respiratoires (dont la Grippe) [Lyon] (CNR - laboratoire associé), Institut des Agents Infectieux [Lyon] (IAI), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), CHU Pontchaillou [Rennes], Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), ANR-20-COVI-0002,CORaDiag,COVID 19 Rapid diagnosis test (development and clinical validation in 7 weeks)(2020), École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI Paris), Université Paris sciences et lettres (PSL)-Collège de France (CdF (institution))-École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Collège de France (CdF (institution))-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université Paris sciences et lettres (PSL)-Collège de France (CdF (institution))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Microbiology (medical), medicine.medical_specialty, 2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), Health Personnel, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), [SDV]Life Sciences [q-bio], Pneumonia, Viral, Sars-cov-2, Betacoronavirus, 03 medical and health sciences, Health personnel, 0302 clinical medicine, High-risk exposure, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Personal protective equipment, medicine, Humans, Risk exposure, Transmission, 030212 general & internal medicine, Letter to the Editor, Pandemics, ComputingMilieux_MISCELLANEOUS, 0303 health sciences, 030306 microbiology, Transmission (medicine), business.industry, COVID-19, 3. Good health, Infectious Diseases, Cohort, Emergency medicine, In-hospital workers, Human medicine, Coronavirus Infections, business
Abstract

International audience

Published
2021
Full Text
View/download PDF

22. The Design and Implementation of the ECOVIR Project: A Primary Health Care Surveillance System to Strengthen Co-Detection of Respiratory Viruses in Normandy.

Author

Petat, Hortense, Schuers, Matthieu, Corbet, Sandrine, Humbert, Xavier, Le Bas, François, Marguet, Christophe, Pellerin, Lucille, Rabiaza, Andry, Vabret, Astrid, and Ar Gouilh, Meriadeg

Subjects
PRIMARY health care, AGE distribution, YOUNG adults, MIDDLE-aged persons, GENERAL practitioners, COVID-19, PLANT viruses
Abstract

Acute respiratory infections (ARIs) need to be better understood and treated, as they are critical to public health, especially during crises such as the SARS-CoV2 pandemic. These are the most abundant infections in the general population and are seen primarily in primary care by general practitioners (GPs). Many different viruses are involved, according to epidemic variations. Viral co-detections account for a significant proportion of ARIs in hospital cohorts. The objective of the ECOVIR cohort was to study viral co-detections by setting up a biobank of respiratory tract samples from patients consulting their general practitioner for ARI symptoms. We report here on the course of the study: the design, the conduct, and the difficulties encountered. ECOVIR (Etude des CO-detections VIrales dans les prélèvements Respiratoires) was a prospective, multicenter cohort conducted in France during two epidemic seasons (2018–2019 and 2019–2020). We recruited GPs. Each GP investigator (GPI) saw patients weekly for examination, clinical data collection, and nasopharyngeal swabbing. Each sample was sent to the virology unit for biobanking and molecular analysis. Clinical and sociodemographic data were collected 7 days after inclusion. ECOVIR involved 36 GPIs. Patients with symptoms of an ARI were included (n = 685). The median number of inclusions was 16 patients per GPI over both seasons (IC25–75% [4.75; 27]). Patients aged 18 to 64 years were the most numerous (57%), followed by children (30%), and the elderly (13% over 65 years). This age distribution emphasizes the young adult and middle-aged population. Residents participated in the project and called patients on day 7 to obtain clinical and sociodemographic data. Our study triggered the creation of an original network, which plans to establish a functional link between research and primary health care. Primary care is unfortunately poorly represented in research protocols, particularly in respiratory infections, even though it is a cornerstone of our French health care system, as demonstrated every day in this period of crisis. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

23. Use of LoopDeelab during the COVID-19 Pandemic: An Innovative Device for Field Diagnosis.

Author

Dossou, Nefert Candace, Gaubert, Isidore, Maille, Elodie, Morello, Remy, Cassier, Renaud, Schanen, Cécile, Dutheil, Jean-Jacques, Rocque, Louis-Marie, Vabret, Astrid, and Ar Gouilh, Meriadeg

Subjects
COVID-19 pandemic, COVID-19 testing, TECHNOLOGICAL innovations, DIAGNOSIS, DIAGNOSTIC use of polymerase chain reaction
Abstract

Rapid and accurate diagnosis of SARS-CoV-2 infection is essential for the management of the COVID-19 outbreak. RT-LAMP LoopDeetect COVID-19 (LoopDeescience, France) is a rapid molecular diagnostic tool which operates with the LoopDeelab (LoopDeescience, France) device. RAPID COVID is a prospective double-blind research protocol which was conducted to evaluate the concordance between Loopdeetect COVID-19 and RT-PCR Allplex 2019 n-Cov (Seegene, Korea). Between 11 May 2020 and 14 June 2021, a total of 1122 nasopharyngeal swab specimens were collected, of which 741 were finally analysed. There were 32 "positive" and "indeterminate" RT-PCR results. The intrinsic performances of Loopdeetect COVID-19 are equivalent to other commercial RT-LAMP PCR COVID-19 kits, with a sensitivity and specificity of 69.23% [CI 95%: 48.21–85.67] and 100% [CI 95%: 99.58–100.00], respectively. To the best of our knowledge, LoopDeelab is the only LAMP PCR diagnostic device allowing such a fast and reliable analysis with low-cost equipment; this makes it a new and innovative technology, designed for field use. This device being portable, the development of other detection kits will be useful for the management of epidemics with a high attack rate and would facilitate the rapid application of health measures. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

26. Detection of the new human coronavirus HKU1: a report of 6 cases

Author

Vabret, Astrid, Dina, Julia, Gouarin, Stephanie, Petitjean, Joelle, Corbet, Sandrine, and Freymuth, Francois

Subjects
Coronavirus infections -- Risk factors, Coronavirus infections -- Diagnosis, Coronavirus infections -- Care and treatment, Health, Health care industry
Published
2006

27. Molecular epidemiology of SARS-associated coronavirus, Beijing

Author

Liu, Wei, Tang, Fang, Fontanet, Arnaud, Zhan, Lin, Wang, Tian-Bao, Zhang, Pan-He, Luan, Yi-He, Cao, Chao-Yang, Zhao, Qiu-Min, Wu, Xiao-Ming, Xin, Zhong-Tao, Zuo, Shu-Qing, Baril, Laurence, Vabret, Astrid, Shao, Yi-Ming, Yang, Hong, and Cao, Wu-Chun

Subjects
World Health Organization, Severe acute respiratory syndrome, Epidemiology, Beijing, China -- Health aspects
Abstract

Single nucleotide variations (SNVs) at 5 loci (17564, 21721, 22222, 23823, and 27827) were used to define the molecular epidemiologic characteristics of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) from Beijing [...]

Published
2005

28. Human coronavirus NL63, France

Author

Vabret, Astrid, Mourez, Thomas, Dina, Julia, van der Hoek, Lia, Gouarin, Stephanie, Petitjean, Joelle, Brouard, Jacques, and Freymuth, Francois

Subjects
Coronaviruses -- Research
Abstract

The human coronavirus NL63 (HCoV-NL63) was first identified in the Netherlands, and its circulation in France has not been investigated. We studied HCoV-NL63 infection in hospitalized children diagnosed with respiratory [...]

Published
2005

29. Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy

Author

Parienti, Jean-Jacques, Massari, Veronique, Descamps, Diane, Vabret, Astrid, Bouvet, Elisabeth, Larouze, Bernard, and Verdon, Renaud

Subjects
Nevirapine -- Health aspects, HIV infection -- Care and treatment, Highly active antiretroviral therapy -- Health aspects, Reverse transcriptase inhibitors -- Health aspects, Reverse transcriptase inhibitors -- Research, Health, Health care industry
Published
2004

32. Coronavirus 229E--related pneumonia in immunocompromised patients

Author

Pene, Frederic, Merlat, Annabelle, Vabret, Astrid, Rozenberg, Flore, Buzyn, Agnes, Dreyfus, Francois, Cariou, Alain, Freymuth, Francois, and Lebon, Pierre

Subjects
Pneumonia -- Causes of, Bacterial pneumonia -- Causes of, Coronavirus infections -- Influence, Immunodeficiency -- Diseases, Communicable diseases -- Research, Health, Health care industry
Published
2003

33. An outbreak of coronavirus OC43 respiratory infection in Normandy, France. (Major Article)

Author

Vabret, Astrid, Mourez, Thomas, Gouarin, Stephanie, Petitjean, Joelle, and Freymuth, Francois

Subjects
Coronavirus infections -- Research, Coronavirus infections -- Physiological aspects, Coronavirus infections -- Diagnosis, Polymerase chain reaction -- Usage, Respiratory tract infections -- Physiological aspects, Respiratory tract infections -- Causes of, Health, Health care industry
Published
2003

39. SOFIA®RSV: prospective laboratory evaluation and implementation of a rapid diagnostic test in a pediatric emergency ward

Author

Tran, Léa, Tournus, Céline, Dina, Julia, Morello, Rémy, Brouard, Jacques, Vabret, Astrid, Service de Pédiatrie Médicale [Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Unité de Recherche Risques Microbiens (U2RM), Normandie Université (NU)-Normandie Université (NU), Groupe de Recherche sur l'Adaptation Microbienne (GRAM 2.0), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Université de Caen Normandie (UNICAEN), Normandie Université (NU), Service de Virologie [CHU Caen], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), and Unité de Biostatistique et de Recherche Clinique (UBRC)

Subjects
Adult, Adolescent, Point-of-Care Systems, Respiratory Syncytial Virus Infections, Respiratory syncytial virus, [SDV.MP.PRO]Life Sciences [q-bio]/Microbiology and Parasitology/Protistology, lcsh:Infectious and parasitic diseases, Respiratory infection, Humans, lcsh:RC109-216, Prospective Studies, Pediatric emergency ward, Child, ComputingMilieux_MISCELLANEOUS, [SDV.MP.MYC]Life Sciences [q-bio]/Microbiology and Parasitology/Mycology, Diagnostic Tests, Routine, Pediatric Emergency Medicine, Rapid diagnostic tests, Infant, Reproducibility of Results, SOFIA®RSV, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, Point-of-care testing, Child, Preschool, Respiratory Syncytial Virus, Human, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, Bronchiolitis, Seasons, Emergency Service, Hospital, Laboratories, Research Article
Abstract

Background Respiratory syncytial virus (RSV) is responsible for severe respiratory infections and higher costs in medical care. The two aims of this work were to assess the performances of SOFIA®RSV tests in “real-life-laboratory” conditions (study 1) and implemented at point-of-care testing in a pediatric emergency department (ED, study 2), during two consecutive winter seasons. Methods In study 1, fresh nasopharyngeal swabs from patients of all ages were sampled in 1.5 ml of Universal virological Transport Medium (UTM) and prospectively tested using SOFIA®RSV tests. In study 2, conducted in a pediatric ED, nasopharyngeal swabs were placed in 3 ml of UTM. All SOFIA®RSV tests were confirmed by molecular testing, considered as reference method. The epidemiological and clinical features of tested patients, as well as the care of these patients after obtaining quick results were evaluated. Results The sensitivities of SOFIA®RSV in infants (aged under 24 months) performed in the laboratory and in the pediatric ED were respectively 95% (95% CI: 86.8–98.1) and 74.8% (95% CI: 68.0–80.9) compared to PCR. In study 1, the sensitivity among children (from 2 to 15 years old) and adults (above 15 years old) dropped to 45% (95% CI: 23.1–68.5) and 59% (95% CI: 32.9–81.6), respectively. In study 2, there were some differences in bed-management of SOFIA®RSV positive compared to SOFIA®RSV negative infants. Conclusions SOFIA®RSV tests performed in the laboratory and in the pediatric ED show high and satisfactory sensitivities among young children under 24 months, which supports its robustness and reliability. However, the impact of these tests on patient care at point-of-care cannot be clearly assessed when considering the limits of the study 2 design. Electronic supplementary material The online version of this article (doi:10.1186/s12879-017-2557-8) contains supplementary material, which is available to authorized users.

Published
2017
Full Text
View/download PDF

48. Fatal measles without rash in immunocompetent adult, France

Author

Lupo, Julien, Bernard, Sylvain, Wintenberger, Claire, Baccard, Monique, Vabret, Astrid, Antona, Denise, Timsit, Jean-Francois, and Morand, Patrice

Subjects
Measles -- Diagnosis -- Care and treatment -- Case studies -- Complications and side effects, Health
Abstract

To the Editor: The reemergence of measles in Europe is a reminder of the forgotten risk for severe illness and death associated with this disease in industrialized countries. Since 2008, [...]

Published
2012
Full Text
View/download PDF

49. Molecular epidemiology of Enteroviruses and Rhinoviruses in patients with acute respiratory infections in Yaounde, Cameroon.

Author

Kenmoe, Sebastien, Sadeuh‐Mba, Serge Alain, Vernet, Marie‐Astrid, Penlap Beng, Véronique, Vabret, Astrid, and Njouom, Richard

Subjects
RHINOVIRUSES, ENTEROVIRUSES, COXSACKIEVIRUSES, MOLECULAR epidemiology, VIRAL proteins
Abstract

Background: Acute respiratory infections (ARI) are associated with a huge morbidity and mortality worldwide. Rhinoviruses (RVs) and Enteroviruses (EVs) are recognized as leading causes of ARI. Objectives: The present study describes the molecular epidemiology of RVs and EVs in Cameroon over a 3‐year surveillance period. Methods: From September 2011 to October 2014, nasopharyngeal swabs were collected from patients with influenza‐like illness (ILI) and severe acute respiratory infections (SARI). Two sub‐genomic regions of the EVs and RVs were targeted for molecular characterization. These included the most conserved 5′‐untranslated region (5′UTR) and the viral protein 4/viral protein 2 transition region (VP4/VP2). Results: A total of 974 samples were collected. Children ≤5 years accounted for 85.7% (835/974) of all participants. Among them, 160 (16.4%) were positive for RVs and/or EVs. RVs and/or EVs were significantly more identified in ILI compared to SARI patients (P =.015). Both viruses co‐circulated all year long with a marked increase of occurrence during rainy and cold season. All RV species were found to circulate in Cameroon, with 6, 10 and 6 virus types belonging to the RV‐A, RV‐B and RV‐C, respectively. EV species identified comprised EV‐A (1 Coxsackie virus A5), EV‐B (1 Coxsackie virus A9 and 2 Coxsackie virus B1) and EV‐C (1 EV‐C117). Conclusions: This study indicates a strong year‐round occurrence of EV and RV associated respiratory infections in Cameroon. Molecular characterization identified a wide variety of RVs and EVs in patients with ARI in Cameroon. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

50. Emerging resistance mutations in PI-naive patients failing an atazanavir-based regimen (ANRS multicentre observational study)

Author

Lambert-Niclot, L, Grude, C, Chaix, L., Charpentier, L, Reigadas, C, Le Guillou-Guillemette, L, Rodallec, C, Maillard, Pascale, Dufayard, C, Mourez, C, Mirand, C, Guinard, L, Montes, S, Vallet, L, Marcelin, Marc, Descamps, L, Flandre, C, Delaugerre, L, Alloui, Chakib, Descamps, Diane, Charpentier, Charlotte, Visseaux, Benoit, Krivine, Anne, Bouviers-Alias, Ali, Pallier, Coralie, Soulié, Cathia, Wirden, Marc, Marcelin, Anne, Calvez, Vincent, Morand, Laurence, Lambert-Niclot, Sidonie, Fofana, Djeneba, Mahjoub, Nadia, Delaugerre, Constance, Chaix, Marie, Amiel, Corinne, Schneider, Veronique, Roussel, Catherine, Le Guillou-Guillemette, Hélène, Courdavault, Laurence, Reigadas, Sandrine, Recordon-Pinson, Patricia, Fleury, Hervé, Vallet, Sophie, Dina, Julia, Vabret, Astrid, Mirand, Audrey, Henquell, Cécile, Auvray, Christelle, de Rougemont, Alexis, Giraudon, Helene, Si-Mohammed, Ali, Mathez, Dominique, Signori-Schmuck, Anne, Morand, Patrice, Bocket, Laurence, Trabaud, Anne, Montes, Brigitte, Le Guen, Laura, Rodallec, Audrey, Ferré, Virginie, Jeulin, Hélène, SCHVOERER, Evelyne, Dufayard, Jacqueline, Allardet-Servent, Annick, carles, Marie, Guinard, Jérôme, Guigon, Aurélie, Giraudeau, Genevieve, Beby-Defaux, Agnès, Maillard, Anne, Plantier, Jean Christophe, Leoz, Marie, Mourez, Thomas, Bourlet, Thomas, Fafi-Kremer, Samira, Chiabrando, Julie, Raymond, Stéphanie, Izopet, Jacques, Barin, Francis, Marque-Juillet, Stéphanie, Yerly, Sabine, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Pierre et Marie Curie - Paris 6 - UFR de Médecine Pierre et Marie Curie (UPMC), Université Pierre et Marie Curie - Paris 6 (UPMC), Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Hôpital Pellegrin, CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Centre hospitalier universitaire de Nantes (CHU Nantes), Hôpital Pontchaillou, Centre Hospitalier Universitaire de Nice (CHU Nice), CHU Rouen, Normandie Université (NU), CHU Clermont-Ferrand, Centre Hospitalier Régional d'Orléans (CHRO), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Hôpital de la Cavale Blanche - CHRU Brest (CHU - BREST ), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Laboratoire Bordelais de Recherche en Informatique (LaBRI), Université de Bordeaux (UB)-Centre National de la Recherche Scientifique (CNRS)-École Nationale Supérieure d'Électronique, Informatique et Radiocommunications de Bordeaux (ENSEIRB), Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10, Service de virologie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Epidémiologie, stratégies thérapeutiques et virologie cliniques dans l'infection à VIH, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département de Mathématiques et Applications - ENS Paris (DMA), École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS), Département d'Astrophysique, de physique des Particules, de physique Nucléaire et de l'Instrumentation Associée (DAPNIA), Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Laboratoire de Virologie [CHU Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Génétique et Ecologie des Virus, Génétique des Virus et Pathogénèse des Maladies Virales, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), UFR des Sciences de Santé (Université de Bourgogne), Université de Bourgogne (UB), CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hémodynamique, Interaction Fibrose et Invasivité tumorales Hépatiques (HIFIH), Université d'Angers (UA), Centre Hospitalier Victor Dupouy, Microbiologie cellulaire et moléculaire et pathogénicité (MCMP), Université Bordeaux Segalen - Bordeaux 2-Centre National de la Recherche Scientifique (CNRS), CHU Bordeaux [Bordeaux], Laboratoire Universitaire de Biodiversité et Ecologie Microbienne (LUBEM), Université de Brest (UBO), Laboratoire de Virologie Humaine et Moléculaire [Caen], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Groupe de Recherche sur l'Adaptation Microbienne (GRAM 2.0), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Université de Caen Normandie (UNICAEN), Laboratoire Microorganismes : Génome et Environnement (LMGE), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre National de la Recherche Scientifique (CNRS), Laboratoire de sérologie-virologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Hôpital Raymond Poincaré [AP-HP], Institut de biologie structurale (IBS - UMR 5075 ), Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Département de virologie [Grenoble], Centre Hospitalier Universitaire [Grenoble] (CHU), Service de Virologie [Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Epidémiologie, Démographie et Sciences Sociales: santé reproductive, sexualité et infection à VIH (Inserm U569), Epidémiologie, sciences sociales, santé publique (IFR 69), Université Paris 1 Panthéon-Sorbonne (UP1)-Université Paris-Sud - Paris 11 (UP11)-École des hautes études en sciences sociales (EHESS)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris 1 Panthéon-Sorbonne (UP1)-Université Paris-Sud - Paris 11 (UP11)-École des hautes études en sciences sociales (EHESS)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut national d'études démographiques (INED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de Chimie Physique et Microbiologie pour les Matériaux et l'Environnement (LCPME), Institut de Chimie du CNRS (INC)-Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Observatoire des Programmes Communautaires de Développement Rural (US ODR), Institut National de la Recherche Agronomique (INRA), Institut Pasteur de Nouvelle-Calédonie, Réseau International des Instituts Pasteur (RIIP), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Ecophysiologie Végétale, Agronomie et Nutritions (EVA), Institut National de la Recherche Agronomique (INRA)-Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU), Groupe Immunité des Muqueuses et Agents Pathogènes (GIMAP), Université Jean Monnet [Saint-Étienne] (UJM), Interaction virus-hôte et maladies du foie, Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Claude de Préval (ICP), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Toulouse [Toulouse]-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées, Université de Tours (UT), Centre Hospitalier de Versailles André Mignot (CHV), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Université de Bordeaux (UB)-École Nationale Supérieure d'Électronique, Informatique et Radiocommunications de Bordeaux (ENSEIRB)-Centre National de la Recherche Scientifique (CNRS), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), École normale supérieure - Paris (ENS-PSL), Microbiologie Fondamentale et Pathogénicité (MFP), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Recherche Agronomique (INRA), Université Jean Monnet - Saint-Étienne (UJM), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7), Université de Tours, Service de Virologie [CHU Pitié-Salpêtrière], Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Lycée agricole La Touche, Hôpital Bichat - Claude Bernard, Centre National de la Recherche Scientifique (CNRS)-École Nationale Supérieure d'Électronique, Informatique et Radiocommunications de Bordeaux (ENSEIRB)-Université Sciences et Technologies - Bordeaux 1-Université Bordeaux Segalen - Bordeaux 2, Memo-Flu-ARDS Study Group, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], École normale supérieure - Paris (ENS Paris)-Centre National de la Recherche Scientifique (CNRS), CHU Pitié-Salpêtrière [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), CHU Tenon [APHP], Hôpital d'Argenteuil, Laboratoire Microorganismes : Génome et Environnement - Clermont Auvergne (LMGE), Université Clermont Auvergne (UCA)-Centre National de la Recherche Scientifique (CNRS), AP-HP Hôpital Raymond Poincaré [Garches], Unit for Virus Host-Cell Interactions [Grenoble] (UVHCI), Université Joseph Fourier - Grenoble 1 (UJF)-European Molecular Biology Laboratory [Grenoble] (EMBL)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de virologie moléculaire et structurale, CHU Grenoble, Laboratoire de virologie [CHU Lille], Université Panthéon-Sorbonne (UP1)-Université Paris-Sud - Paris 11 (UP11)-École des hautes études en sciences sociales (EHESS)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Panthéon-Sorbonne (UP1)-Université Paris-Sud - Paris 11 (UP11)-École des hautes études en sciences sociales (EHESS)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut national d'études démographiques (INED), Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Centre national de référence du VIH INSERM U966, Centre Hospitalier de Versailles (CHV), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)

Subjects
0301 basic medicine, Microbiology (medical), Adult, Male, medicine.medical_specialty, 030106 microbiology, Atazanavir Sulfate, HIV Infections, Emtricitabine, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Abacavir, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Internal medicine, Drug Resistance, Viral, medicine, Humans, Pharmacology (medical), 030212 general & internal medicine, Treatment Failure, Tenofovir, ComputingMilieux_MISCELLANEOUS, Retrospective Studies, Pharmacology, business.industry, virus diseases, Lamivudine, HIV Protease Inhibitors, Middle Aged, Viral Load, Resistance mutation, Dideoxynucleosides, 3. Good health, Atazanavir, Regimen, Drug Combinations, Infectious Diseases, Mutation, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, HIV-1, Ritonavir, business, Viral load, medicine.drug
Abstract

Background Atazanavir is a PI widely used as a third agent in combination ART. We aimed to determine the prevalence and the patterns of resistance in PI-naive patients failing on an atazanavir-based regimen. Methods We analysed patients failing on an atazanavir-containing regimen used as a first line of PI therapy. We compared the sequences of reverse transcriptase and protease before the introduction of atazanavir and at failure [two consecutive viral loads (VLs) >50 copies/mL]. Resistance was defined according to the 2014 Agence Nationale de Recherche sur le SIDA et les Hepatites Virales (ANRS) algorithm. Results Among the 113 patients, atazanavir was used in the first regimen in 71 (62.8%) patients and in the first line of a PI-based regimen in 42 (37.2%). Atazanavir was boosted with ritonavir in 95 (84.1%) patients and combined with tenofovir/emtricitabine or lamivudine (n = 81) and abacavir/lamivudine or emtricitabine (n = 22). At failure, median VL was 3.05 log10 copies/mL and the median CD4+ T cell count was 436 cells/mm3. The median time on atazanavir was 21.2 months. At failure, viruses were considered resistant to atazanavir in four patients (3.5%) with the selection of the following major atazanavir-associated mutations: I50L (n = 1), I84V (n = 2) and N88S (n = 1). Other emergent PI mutations were L10V, G16E, K20I/R, L33F, M36I/L, M46I/L, G48V, F53L, I54L, D60E, I62V, A71T/V, V82I/T, L90M and I93L/M. Emergent NRTI substitutions were detected in 21 patients: M41L (n = 2), D67N (n = 3), K70R (n = 1), L74I/V (n = 3), M184V/I (n = 16), L210W (n = 1), T215Y/F (n = 3) and K219Q/E (n = 2). Conclusions Resistance to atazanavir is rare in patients failing the first line of an atazanavir-based regimen according to the ANRS. Emergent NRTI resistance-associated mutations were reported in 18% of patients.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results